Mumbai, October 27 (Udaipur Kiran): Shares of Zydus Lifesciences Ltd traded higher on Monday after the company announced that it has received a Notice of Compliance (NoC) from Health Canada for its generic Mesalamine suppositories 1000 mg, used in the treatment of mild to moderate ulcerative proctitis.
The stock was trading at ₹1,013.00, up ₹7.35 or 0.73%, from its previous close of ₹1,005.65 on the BSE. The scrip opened at ₹1,006.05 and touched an intraday high of ₹1,013.00 and low of ₹1,003.50, with about 15,609 shares traded on the counter.
The BSE Group ‘A’ stock with a face value of ₹1 has a 52-week high of ₹1,059.00 (September 19, 2025) and a 52-week low of ₹797.05 (April 7, 2025). The company’s market capitalisation stands at ₹1,01,845.97 crore. The promoters hold 74.99%, while institutions and non-institutions hold 18.20% and 6.80%, respectively.
The company stated that ZDS – Mesalamine suppositories will be manufactured at its Changodar facility in Ahmedabad, Gujarat. According to IQVIA MAT June 2025, Mesalamine suppositories recorded annual sales of 4.86 million CAD in the Canadian market.
Zydus Lifesciences (formerly Cadila Healthcare) is an integrated pharmaceutical company engaged in research, development, production, marketing, and distribution of pharmaceutical products across multiple therapeutic areas.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
